Earnings ·
Immuneering Corporation reported financial results for the quarter ended June 30, 2026
IMRXImmuneering Corp
Immuneering Corporation reported financial results for the quarter ended June 30, 2026. The company ended Q2 with $182.7 million in cash and marketable securities, providing an anticipated runway into 2029. Research and development expenses increased to $14.0 million from $10.5 million in the prior year period, while general and administrative expenses rose to $5.0 million from $4.3 million. The net loss attributable to common stockholders was $17.3 million, or $0.27 per share, compared to a $14.4 million loss, or $0.40 per share, in the same quarter of 2025. Operationally, Immuneering announced it has dosed the first patient in its pivotal Phase 3 MAPKeeper 301 trial for atebimetinib in combination with chemotherapy for first-line pancreatic cancer. The company also highlighted compelling Phase 2a data presented at ASCO showing a 17.3-month median overall survival and appointed Andrew Gengos as Chief Financial Officer. Immuneering Corporation is a late-stage clinical oncology company focused on developing Deep Cyclic Inhibitors to treat RAS, RAF, and MAPK-driven cancers.